PCM
ALNY icon

Polymer Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Polymer Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,070
Closed -$1.22M – 819
2025
Q4 		$1.22M Buy
3,070
+2,262
+280% +$1M 0.13% 191
2025
Q3 		$368K Buy
+808
New +$329K 0.04% 517
2025
Q2 		– Sell
-961
Closed -$259K – 607
2025
Q1 		$259K Buy
+961
New +$247K 0.07% 390

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polymer Capital Management's ALNY Position: Q1 2026 in Review

Polymer Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 3,070 shares — an estimated $1.22M sold.

Polymer Capital Management first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $1.22M in Q4 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Polymer Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Polymer Capital Management sold 3,070 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.22M.
  • Polymer Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Polymer Capital Management's Alnylam Pharmaceuticals position peaked at $1.22M in Q4 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Polymer Capital Management's 13F filing for Q1 2026, filed 14 May 2026.